+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus



Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus



Arthritis and Rheumatism 48(2): 495-506



To determine the immunologic effects of anti-CD154 (CD40L) therapy in the (NZB x NZW)F(1) mouse model of systemic lupus erythematosus. Twenty-week-old and 26-week-old (NZB x NZW)F(1) mice were treated with continuous anti-CD154 therapy. Mice were followed up clinically, and their spleens were studied at intervals for B and T cell numbers and subsets and frequency of anti-double-stranded DNA (anti-dsDNA)-producing B cells. T cell-dependent immunity was assessed by studying the humoral response to the hapten oxazolone. IgG anti-dsDNA antibodies decreased during therapy and disease onset was delayed, but immune tolerance did not occur. During treatment, there was marked depletion of CD19+ cells in the spleen; however, autoreactive IgM-producing B cells could still be detected by enzyme-linked immunospot assay. In contrast, few IgG- and IgG anti-dsDNA-secreting B cells were detected. Eight weeks after treatment cessation, the frequency of B cells producing IgG anti-dsDNA antibodies was still decreased in 50% of the mice, and activation and transition of T cells from the naive to the memory compartment were blocked. Anti-CD154 treatment blocked both class switching and somatic mutation and induced a variable period of relative unresponsiveness of IgG anti-dsDNA-producing B cells, as shown by decreased expression of the CD69 marker and failure to generate spontaneous IgG anti-dsDNA-producing hybridomas. Treated mice mounted an attenuated IgM response to the hapten oxazolone and produced no IgG antioxazolone antibodies. Anti-CD154 is a B cell-depleting therapy that affects multiple B cell subsets. Activation of both B and T cells is prevented during therapy. After treatment cessation, autoreactive B cells progress through a series of activation steps before they become fully competent antibody-producing cells. The general immunosuppression induced during treatment will need to be taken into account when using B cell-depleting regimens in humans.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045904037

Download citation: RISBibTeXText

PMID: 12571860

DOI: 10.1002/art.10929


Related references

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 46(12): 3251-3258, 2002

Limiting dilution analysis of Epstein-Barr virus infectable B cells secreting anti-Ro/SSA and anti-La/SSB antibodies in neonatal lupus erythematosus and systemic lupus erythematosus. Journal of Autoimmunity 6(4): 481-494, 1993

Estrogen does not regulate CD154 mRNA stability in systemic lupus erythematosus T cells. Lupus 15(12): 852-857, 2006

IL-10 production in B cells is confined to CD154+ cells in patients with systemic lupus erythematosus. Journal of Autoimmunity 23(4): 379-383, 2004

Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. International Immunology 14(11): 1303-1311, 2002

Prolactin effect on CD69 and CD154 expression by CD4+ cells from systemic lupus erythematosus patients. Clinical and Experimental Rheumatology 23(6): 769-777, 2006

CD154 expression and mRNA stability of activated CD4-positive T cells in patients with systemic lupus erythematosus. Modern Rheumatology 13(3): 220-226, 2003

Activation of mesangial cells by platelets in systemic lupus erythematosus via a CD154-dependent induction of CD40. Kidney International 68(5): 2068-2078, 2005

Anti ro ss a and anti la ss b autoantibody levels in relation to systemic lupus erythematosus disease activity and congenital heart block a longitudinal study comprising two consecutive pregnancies in a patient with systemic lupus erythematosus. Arthritis & Rheumatism 35(8): 953-959, 1992

T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Current Rheumatology Reports 2(1): 24-31, 2000

Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. Journal of Immunology 178(3): 1960-1966, 2007

Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Science Translational Medicine 2(47): 47ra63, 2010

Experimental models of systemic lupus erythematosus: anti-dsDNA in murine lupus. Rheumatology 44(9): 1086-1089, 2005

Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis and Rheumatism 62(8): 2443-2457, 2010

Correlation between systemic lupus erythematosus and anti-convulsants. Case of systemic lupus erythematosus with aggravated lupus and granulocytopenia caused by diphenyl-hydantoin. Naika. Internal Medicine 26(5): 989-994, 1970